Skip to content
DataLookout
Menu

NCT07597473

Dymista in Chinese Adolescents

StatusCompleted
PhasePhase 4
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Trial completed
    • Primary completion date changed from estimate of Oct 2026 to Sep 19, 2026
    • Study completion date changed from estimate of Oct 2026 to Oct 13, 2026
  2. Notable Eligibility criteria expanded, about 43 words Show 5 more changesShow less
    • Enrollment closed, study ongoing
    • Primary and study completion moved earlier from Mar 2027 to Oct 2026
    • Study sites: 15 to 14
    • Secondary endpoints: details revised at 3 of 3 entries
    • Collaborators: details revised at 1 of 1 entry
  3. Notable Recruitment opened
    • Start date changed from estimate of Apr 30, 2026 to May 8, 2026
    • Site details revised at 15 of 15 sites
    v2
  4. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Change from baseline in AM+PM combined reflective Total Nasal Symptom Score (rTNSS).
Timeframe: From enrollment to end of treatment at 2 weeks.

Secondary (3)

Changes from baseline in AM+PM combined reflective TOSS
Changes from baseline in AM+PM combined reflective T7SS
Changes from baseline in individual nasal symptom scores (itchy nose, nasal congestion, runny nose, sneezing) and ocular symptom scores (itchy eyes, watery eyes, eye redness)

Arms and interventions

Treatment with intranasal spray of DymistaExperimental

The study drug will be delivered as an intranasal spray of Dymista (137 μg of azelastine hydrochloride and 50 μg of fluticasone propionate) in each nostril, BID, approximately 12 hours apart at AM and PM. The formulation is a white suspension which contains 120 sprays per bottle. The liquid medicine is sprayed out in a mist after actuator is pressed.

Drugs: Treatment with 137 µg azelastine hydrochloride and 50 μg of fluticasone propionate

Sites

14 sites in 1 country